A major focus of Dr. Srivastava’s research is the use of extracellular vesicles (EVs) as a therapeutic tool in CNS and traumatic disorders. EVs carry proteins and genetic material that can profoundly modify cellular function and may possess regenerative capabilities. Use of cell derived-EVs presents distinct advantages over the use of cells, as they may be less likely to produce a pulmonary first pass effect after transfusion. Similarly, the possibility to replace cell therapy with EV therapy would overcome the problem of graft rejection, which is always a hurdle in diseases with strong immunological components. Dr. Srivastava’s lab has expertise in isolating EVs in current Good Manufacturing Practice (cGMP) compliant manner. He is also investigating the molecular mechanisms by which EVs modulate cellular function.